Edition:
United States

I'rom Group Co Ltd (2372.T)

2372.T on Tokyo Stock Exchange

1,644JPY
10:14pm EDT
Change (% chg)

¥82 (+5.25%)
Prev Close
¥1,562
Open
¥1,570
Day's High
¥1,661
Day's Low
¥1,570
Volume
236,200
Avg. Vol
228,738
52-wk High
¥1,992
52-wk Low
¥915

Latest Key Developments (Source: Significant Developments)

I'rom Group fully acquires CMAX Clinical Research Pty for A$6.2 mln
Tuesday, 22 Aug 2017 11:44pm EDT 

Aug 23 (Reuters) - I'rom Group Co Ltd <2372.T>:* Says it fully acquired 61 percent owned CMAX Clinical Research Pty Ltd for A$6.2 million from IDT Australia Limited on Aug. 23 .  Full Article

I'rom Group unit ID Pharma concludes iPS cell generation technology licensing agreement with UK-based Axol Bioscience
Tuesday, 11 Jul 2017 05:41am EDT 

July 11 (Reuters) - I'rom Group Co Ltd <2372.T>:Says co's wholly owned unit, ID Pharma, concluded an iPS cell generation technology licensing agreement with UK-based Axol Bioscience Ltd .Says unit grants non-exclusive rights of iPS cell related research, sales and service and sublicense rights to Axol Bioscience Ltd .Says unit will receive upfront payments, iPS cell sales and service related income and royalty from Axol Bioscience Ltd .  Full Article

I'rom Group unit to conclude licensing agreement on iPS Cell Generation Technology with global mega pharma
Wednesday, 24 May 2017 02:57am EDT 

May 24 (Reuters) - I'rom Group Co Ltd <2372.T> ::* Says co's unit ID Pharma Co Ltd plans to concludes licensing agreement on iPS Cell Generation Technology with global mega pharma.  Full Article

I'rom Group unit ID Pharma concludes licensing agreement on Sendai Virus Vector technology with U.S.-based Elixirgen
Monday, 15 May 2017 11:12pm EDT 

May 16 (Reuters) - I'rom Group Co Ltd <2372.T>:* Says unit ID Pharma Co., Ltd. concluded licensing agreement on Sendai Virus Vector technology With U.S.-based Elixirgen, LLC.* Says unit ID Pharma Co., Ltd. grants Elixirgen non-exclusive rights to use Sendai Virus Vector technology to make products with Elixirgen's genes for research purpose and rights to sell the products.* Says unit ID Pharma Co., Ltd. will receive upfront payment and usage charge from Elixirgen.  Full Article

I'rom Group unit signs license contract with Mayo Clinic on iPS cells
Monday, 3 Apr 2017 03:10am EDT 

I'rom Group Co Ltd <2372.T> :Says its unit ID Pharma Co Ltd signs license contract with US-based hospital Mayo Clinic, regarding iPS cells related technology.  Full Article

I'rom Group to fully acquire Ethic Co Ltd via stock swap
Friday, 31 Mar 2017 04:40am EDT 

I'rom Group Co Ltd <2372.T>: Says it will fully acquire Ethic Co Ltd via stock swap . Says one share of Ethic Co Ltd will be exchanged into 10 shares of the co .Says effective June 1.  Full Article

I'rom Group says exercise of warrants
Sunday, 20 Nov 2016 10:28pm EST 

I'rom Group Co Ltd <2372.T>:Says 800,000 of its 9th series warrants were exercised into 800,000 shares on Nov. 21.  Full Article

I'rom Group unit gets patent grant in Japan and U.S. for cells production technology
Friday, 18 Nov 2016 01:45am EST 

I'rom Group Co Ltd <2372.T>:Says its unit received patent grant in Japan and the U.S. for production technology of pluripotent stem cells and brown adipose cells.  Full Article

I'rom Group unit announces success in production process of retinal pigment degeneration treatment
Tuesday, 19 Jul 2016 09:35pm EDT 

I'rom Group Co Ltd <2372.T>:Says its wholly owned unit announced success in production process of retinal pigment degeneration treatment, under cooperation with Kyushu University.  Full Article

I'rom Group unit ID Pharma to grant technology license to KOHJIN BIO
Tuesday, 12 Jul 2016 03:16am EDT 

I'rom Group Co Ltd <2372.T>:Says unit ID Pharma to grant non-exclusive rights in Japan regarding technology license for cancer treatment by amplifing dendritic cells, to Japan-based co KOHJIN BIO.  Full Article